Tectonic Therapeutic, Inc. (TECX) jumped 12.33% to $20.92, gaining $2.30, after announcing positive topline results from its Phase 1b Part B clinical trial of TX45 in patients with Group 2 pulmonary hypertension associated with heart failure with reduced ejection fraction (PH-HFrEF).
The preliminary data, based on 14 enrolled patients, showed meaningful improvements in both left heart function and pulmonary hemodynamics—including a 29.2% reduction in pulmonary capillary wedge pressure and a 17.3% increase in cardiac output—and demonstrated that TX45 was well tolerated with no serious adverse events.
On Thursday, TECX opened at $18.75, reached a high of $21.28, and a low of $18.60, compared to the previous close of $18.62 on the Nasdaq. Trading volume surged well above average. The stock's 52-week range is approximately $10.45 - $25.60.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.